PDCD1 and hepatocellular carcinoma: ICM47 and Senegalimassilia anaerobia), as well as a metabolite (galanthaminone), were ascertained as prospective forecasted biomarkers for subsistence in PD-1 inhibitor-treated HCC patients (25).